JG
CNST

Jefferies Group’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Jefferies Group’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,790
Closed -$925 – 1644
2020
Q2 		$925 Buy
+30,790
New +$1.11M 0.01% 781

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group's CNST Position: Q3 2020 in Review

Jefferies Group sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2020, closing a stake of 30,790 shares — an estimated $925 sold.

Jefferies Group first reported a position in CNST in Q2 2020 and held it in 1 quarter. The position peaked at $925 in Q2 2020. 119 funds tracked by Wall St. Rank hold CNST as of Q3 2020.

  • Jefferies Group reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 30,790 Constellation Pharmaceuticals, Inc. shares in Q3 2020, an estimated $925.
  • Jefferies Group first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Jefferies Group's Constellation Pharmaceuticals, Inc. position peaked at $925 in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.